drugset / Trial / NCT04803058
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Timeline
- Start
- 2022-12-14
- Primary completion
- 2026-02-17
- Completion
- 2026-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.